Targeted Oncology

, Volume 13, Issue 2, pp 253–256 | Cite as

Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience

  • Salvatore Alfieri
  • Cristiana Bergamini
  • Roberta Granata
  • Laura Locati
  • Lisa Licitra
  • Paolo Bossi
Therapy in Practice


Retreatment with vismodegib in advanced basal cell carcinoma (BCC) patients who previously discontinued the drug due to disease progression (PD) has not been reported yet. The objective of our report is to determine whether vismodegib is still active when used in BCC patients who progressed during a first vismodegib course (FVC). We conducted a retrospective study on six advanced BCC patients enrolled in a clinical trial (STEVIE, NCT01367665) who discontinued vismodegib due to PD and were then retreated with the same drug. All patients underwent intercurrent therapies between the FVC and the second vismodegib course (SVC). Disease control (complete response, CR; partial response, PR; and stable disease) was achieved in 100% and 80% of cases in FVC and SVC, respectively. The overall response rate was 80% for FVC (50% of CR) and 50% for SVC (only PR). Median treatment duration of FVC and SVC was 19.5 months (range: 13–35) and 8 months (range: 3–14+), respectively. G3-G4 AEs were reported only during SVC (two cases), leading to permanent discontinuation in one case. The median interval between FVC and SVC was 21.5 months (range: 13–30). After a median follow-up of 54 months (range: 46–63) only one patient with metastatic disease had rapid progression, discontinued vismodegib, and died. All other patients are still alive and two are currently on therapy. We concluded that vismodegib rechallenge is feasible and potentially active in advanced BCC patients who previously discontinued the drug due to disease progression.



Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD and Ambra Corti; this assistance was supported by internal funds.

Compliance with Ethical Standards


No funding was received for the preparation of this manuscript.

Conflict of Interest

Paolo Bossi has received consulting fee from Roche. Lisa Licitra has received consulting fees from Eisai, BMS, MSD, Merck-Serono, BI, Novartis, AstraZeneca, Bayer, and Roche; research funding from Eisai, MSD, Merck-Serono, BI, Novartis, AstraZeneca, and Roche; and other financial support from Merck-Serono and Bayer.


  1. 1.
    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72:1021–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma: a review of the literature. Eur J Cancer. 1990;26:73–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164–72.CrossRefGoogle Scholar
  5. 5.
    Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–28.CrossRefPubMedGoogle Scholar
  6. 6.
    Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16:729–36.CrossRefPubMedGoogle Scholar
  7. 7.
    Sekulic A, Hainsworth JD, Lewis KD, Oro AE, Gesierich A, Mortier L, et al. Vismodegib for advanced basal cell carcinoma: duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. J Clin Oncol. 2014;32:5s. (abstr 9081)Google Scholar
  8. 8.
    Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, et al. Acquired resistance to the hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014;71:1005–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Porta C, Paglino C, Grünwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer. 2014;111:1047–53.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14:1175–82.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Medical Oncology 3Fondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  2. 2.Department of Medical Oncology 3University of MilanMilanItaly

Personalised recommendations